Comparative Pharmacology
Head-to-head clinical analysis: ANHYDRON versus FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANHYDRON versus FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE.
ANHYDRON vs FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the sodium-potassium-2 chloride (Na-K-2Cl) cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Fosinopril is an ACE inhibitor that inhibits the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
Oral: 25-100 mg once daily in the morning, or 50-100 mg every other day; maximum 200 mg/day.
1 tablet (fosinopril 10 mg/hydrochlorothiazide 12.5 mg or fosinopril 20 mg/hydrochlorothiazide 12.5 mg) orally once daily. Maximum dose: fosinopril 80 mg/hydrochlorothiazide 50 mg per day.
None Documented
None Documented
Terminal elimination half-life is 60-90 minutes, prolonged in renal impairment (up to 24 hours).
Fosinoprilat: 11.5 h (terminal); Hydrochlorothiazide: 6-15 h (biphasic, terminal phase 10-15 h).
Renal: ~60% unchanged; biliary/fecal: ~40% as metabolites and unchanged drug.
Fosinopril: 45% renal, 55% biliary/fecal; Hydrochlorothiazide: >95% renal (unchanged).
Category C
Category A/B
Thiazide Diuretic
Thiazide Diuretic